Neurology
Benztropine mesylate
Brand: Benztropine Omega®
PBAC's latest decision on Benztropine mesylate: Recommended (2015). Considered for Emergency treatment of acute dystonic reactions.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
2015 → 2015
Eligible population
Patients requiring emergency treatment of acute dystonic reactions.
- Therapy area
- Neurology
- Line of therapy
- Not applicable
- Evidence base
- Other
- Economic model
- Not modelled
- ICER note
- No economic evaluation performed; minor submission for alternative brand listing due to supply issues.
Similar precedents
Open on full dashboard →